OMass CEO Ros Deegan Named as a 2022 In Vivo Rising Leader
Oxford, United Kingdom – 19 April 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is delighted to announce that its CEO, Ros Deegan, has been named as a 2022 In Vivo Rising Leader.
In Vivo’s 30 Rising Leaders was launched in 2020 and is updated annually. The 30 people spotlighted on the list are selected by In Vivo’s editorial team. The focus is on entrepreneurs and innovators who represent the next wave of creativity in healthcare. The list includes academics, CEOs of small and mid-sized companies, rising employees in larger biopharma and medtech businesses, as well as others doing exciting work to drive better health initiatives worldwide.
Ros initially joined OMass has as CEO in May 2019. Since then, the Company has assembled a world-class management and scientific team with expertise in native mass spectrometry and membrane proteins, complemented with expertise in computational chemistry, structural biology, and bioinformatics.
OMass’ patent-protected platform, OdyssION™, combines novel biochemistry techniques, next generation native mass spectrometry and custom chemistry, to interrogate a wide spectrum of targets and how they interact in their native ecosystems, separate from the confounding complexity of the cell. A critical process of target selection has prioritised the most promising targets to be progressed into development. The Company’s selected programs focus on validated targets in immunology & rare disease indications with high unmet need.
Dr Edward Hodgkin, Chairman of OMass said: “Congratulations to Ros for this well-deserved accolade. OMass’ progress and achievements over the last three years is a testament to her leadership. In evolving our strategy, Ros has led the transition of the Company from services to therapeutics, growing our team to 40 employees and expanding our Series A fund raise from £14M to £41.5M (~$60M).”
Ros has more than 20 years’ experience in drug discovery in the biotechnology and pharmaceutical industry, both in the UK and the US. She joined OMass from Bicycle Therapeutics where she served as President, Chief Business Officer and a Director of the US subsidiary of the Company. Ros established the company’s Boston-based subsidiary and over a three-year period led three major transactions. Prior to that, Ros served as Senior Vice President, Business Development and Operations at Trevena, Inc, where she had previously held the role of Head of Finance and Operations. During Ros’ tenure at Bicycle and Trevena, the companies moved four programmes into the clinic, and raised over $300 million in private and public financings. Earlier in her career, Ros was Director of Business Development at GSK in the US and prior to that, served as Director of Operations for GSK’s Centre of Excellence for External Drug Discovery (CEED) and as Marketing Manager for GSK’s UK launch of Bonviva for post-menopausal osteoporosis. Ros is a graduate of Cambridge University and received her MBA with distinction from INSEAD.
Ros Deegan, CEO of OMass said: “Thank you to the In Vivo team for my selection and congratulations to the other entrepreneurs and innovators in the 2022 Leaders list. At OMass we have developed a clear vision and strong values and culture. Our ambitious team combines cutting edge scientific thinking with an innovative and entrepreneurial approach. We are curious and open minded. We care about our work and each other. We are proud of what we are achieving together. We are committed to and passionate about delivering on our mission – to discover new medicines that can make a difference to people’s lives.”
For further information, please contact:
|OMass Therapeutics||Consilium Strategic Communications|
|Rosamond Deegan, Chief Executive Officer
Phone: +44 (0) 1235 527589
|Sue Charles / Chris Gardner / Kumail Waljee
Phone: +44 (0)20 3709 5700
About OMass Therapeutics
OMass Therapeutics is a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes. The Company’s unique technology platform comprises novel biochemistry techniques, next generation native mass spectrometry and custom chemistry. This allows OMass to interrogate not just the target but how it interacts with its native ecosystem, separate from the confounding complexity of the cell. The result is cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bound proteins and GPCRs.
Headquartered in Oxford, UK, OMass is backed by a top-tier investor syndicate, Syncona and Oxford Science Enterprises, having closed a ~$60m Series A funding.